Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 232-152-0 | CAS number: 7789-24-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Based on the findings in an acute oral toxicity study an LD50 of 706 mg/kg bw was determined for male and female rats.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1988-12-28 to 1989-01-24
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Version / remarks:
- February 24, 1987
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPP 81-1 (Acute Oral Toxicity)
- Version / remarks:
- November 1984
- Deviations:
- no
- GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- no
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- lot No.of test material: Lot 129, Drums 1 - 10 - Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Taconic Farms, Germantown, New York
- Weight at study initiation: 201 - 291 g
- Fasting period before study: overnight prior to dosing
- Housing: the animals were individually housed in stainless steel suspended rat cages
- Diet: Purina Laboratory Rodent Chow 5001 ad libitum
- Water: tap water ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature: 66 °F - 73 °F
- Humidity: 24 % to 63 %
- Photoperiod: 12 hour fluorescent light and 12 hour dark cycle - Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 25 % (weight/volume) solution with tap water - Doses:
- males: 500, 700, 1000 mg/kg
females: 500, 1000, 2000 mg/kg - No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: the animals were observed for mortality and clinical signs at 0.5, 1, 2, 3, 4 and 6 hours on the day of dosing and twice daily thereafter for thirteen days; on day 14 they were observed once. Body weights were taken on days 0, 7 and 14 of the study
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight, organ weights. - Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 608 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- ca. 448 - <= 768
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 1 004 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- ca. 472 - <= 1 535
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 706 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- ca. 453 - <= 959
- Mortality:
- Mortality in males
500 mg/kg bw dose group - 1/5
700 mg/kg bw dose group - 4/5
1000 mg/kg bw dose group - 5/5
Mortality in females
500 mg/kg bw dose group - 1/5
1000 mg/kg bw dose group - 2/5
2000 mg/kg bw dose group - 5/5 - Clinical signs:
- other: Clinical signs commonly observed during the study included ataxia, tremors, diarrhea, abdominogenital staining, chromorhinorrhea and chromodacryorrhea. The onset of signs began approximately 1 hour after dosing and continued to be observed until day 6 of
- Gross pathology:
- Gross internal necropsy findings observed in decedents included blood in the intestines of several rats, one of which also had a stomach which was distended with gas. All surviving animals appeared normal at necropsy.
- Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- Under the conditions of the study, a male LD50 value of 608 mg/kg bw, a female LD50 value of 1004 mg/kg bw, and a combined LD50 value of 706 mg/kg bw were obtained when orally administered as a 25 % (weight/volume) solution in tap water.
- Executive summary:
Groups of Sprague-Dawley rats consisting of five males and/or five females were orally administered graded dosages of the test substance as a 25 % (weight/volume) solution in tap water by gavage according to OECD Guideline 401. Males were administered with 500, 700 and 1000 mg/kg bw. Females were administered with 500, 700 and 2000 mg/kg bw.
Mortality occurred in all dose groups. By male rats in dose groups 500, 700 and 1000 mg/kg bw out of 5 rats per dose group 1, 4, 5 rats died respectively. By female rats in dose groups 500, 1000 and 2000 mg/kg bw out of 5 rats per dose group 1, 2, 5 rats died respectively. The predominant clinical signs were ataxia, tremors, diarrhea, abdominogenital staining, chromorhinorrhea and chromodacryorrhea. Most signs of toxicity subsided by day 6 of the study. All surviving animals gained weight by day 14 of the study.
Gross internal necropsy findings observed in decedents included blood in the intestines of several rats, one of which also had a stomach which was distended with gas. Animals which survived treatment and were sacrificed on day 14 appeared normal when necropsied.
Under the conditions of the study, a male LD50 value of 608 mg/kg bw, a female LD50 value of 1004 mg/kg bw, and a combined LD50 value of 706 mg/kg bw were obtained when orally administered as a 25 % (weight/volume) solution in tap water.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 706 mg/kg bw
- Quality of whole database:
- Acceptable and well documented study report, compliant to guideline.
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Data waiving:
- other justification
- Justification for data waiving:
- the study does not need to be conducted because exposure of humans via inhalation is not likely taking into account the vapour pressure of the substance and/or the possibility of exposure to aerosols, particles or droplets of an inhalable size
- Justification for type of information:
- JUSTIFICATION FOR DATA WAIVING
Testing for acute toxicity via the inhalation route is not applicable as human exposure via inhalation is unlikely. According to REACH Regulation No. 1907/2006, Annex VIII, 8.5.2 testing is appropriate if exposure of humans via inhalation is likely taking into account the vapour pressure of the substance and/or the possibility of exposure to aerosols, particles or droplets of an inhalable size. The test substance has a high melting point (848 °C) and a very low vapour pressure (1.22E-021 Pa).
No signs of systemic effects were observed in two acute studies with the structurally similar substances lithium bromide and lithium chloride. Both tests showed that toxic effects due to inhalation can be excluded, although the water solubility favors the uptake of the test substance via the mucous membrane of the respiratory tract.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- the study does not need to be conducted because the physicochemical and toxicological properties suggest no potential for a significant rate of absorption through the skin
- Justification for type of information:
- JUSTIFICATION FOR DATA WAIVING
In accordance with Annex VIII, Section 8.5.3, Column 2 of regulation (EC) No. 1907/2006 (REACH) testing by the dermal route is appropriate if : 1. Inhalation of the substance is unlikely; and 2. skin contact in production and/or use is likely; and 3. the physicochemical and toxicological suggest a potential for a significant rate of absorption through the skin. Lithium fluoride is an inorganic salt with a molecular weight of < 100 and is soluble in water. A log Pow was estimated to be 0.23 for the corresponding anion hydrofluoric acid proving low lipophilicity. Only lipophilic substances are able to penetrate the intact skin barrier. Polar substances and ionic compounds like lithium fluoride are not able to pass the intact epidermis at all. No signs of systemic toxicity were observed in the acute dermal toxicity studies conducted with the read across source substances lithium bromide and lithium chloride. Additionally, lithium fluoride did not show any skin irritating or skin corrosive properties in two in vitro studies (please refer to IUCLID section 7.3.1). Hence, the penetration is not facilitated due to damage of the skin surface. Therefore, it can be reliably assumed that lithium fluoride is not able to pass the stratum corneum. Further in vivo testing would be unethical and cannot be scientifically justified with the above argumentation.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Acute oral toxicity
Groups of Sprague-Dawley rats consisting of five males and/or five females were orally administered graded dosages of the test substance as a 25 % (weight/volume) solution in tap water by gavage according to OECD Guideline 401 and EPA 81-1 acute oral. Males were administered with 500, 700 and 1000 mg/kg bw. Females were administered with 500, 700 and 2000 mg/kg bw.
Mortality occurred in all dose groups. By male rats in dose groups 500, 700 and 1000 mg/kg bw out of 5 rats per dose group 1, 4, 5 rats died respectively. By female rats in dose groups 500, 1000 and 2000 mg/kg bw out of 5 rats per dose group 1, 2, 5 rats died respectively. The predominant clinical signs were ataxia, tremors, diarrhea, abdominogenital staining, chromorhinorrhea and chromodacryorrhea. Most signs of toxicity subsided by day 6 of the study. All surviving animals gained weight by day 14 of the study.
Gross internal necropsy findings observed in decedents included blood in the intestines of several rats, one of which also had a stomach which was distended with gas. Animals which survived treatment and were sacrificed on day 14 appeared normal when necropsied.
Under the conditions of the study, a male LD50 value of 608 mg/kg bw, a female LD50 value of 1004 mg/kg bw, and a combined LD50 value of 706 mg/kg bw were obtained when orally administered as a 25 % (weight/volume) solution in tap water.
Acute inhalation toxicity
Testing for acute toxicity via the inhalation route is not applicable as human exposure via inhalation is unlikely. According to REACH Regulation No. 1907/2006, Annex VIII, 8.5.2 testing is appropriate if exposure of humans via inhalation is likely taking into account the vapour pressure of the substance and/or the possibility of exposure to aerosols, particles or droplets of an inhalable size. The test substance has a the high melting point (848 °C) and a very low vapour pressure (1.22E-021 Pa).
Acute dermal toxicity
In accordance with Annex VIII, Section 8.5.3, Column 2 of regulation (EC) No. 1907/2006 (REACH) testing by the dermal route is appropriate if :
1. Inhalation of the substance is unlikely; and
2. skin contact in production and/or use is likely; and
3. the physicochemical and toxicological properties suggest a potential for a significant rate of absorption through the skin.
Lithium fluoride is an inorganic salt with a molecular weight of < 100 and is soluble in water. A log Pow was estimated to be 0.23 for the corresponding anion hydrofluoric acid proving low lipophilicity. Only lipophilic substances are able to penetrate the intact skin barrier. Polar substances and ionic compounds like lithium fluoride are not able to pass the intact epidermis at all.
No signs of systemic toxicity were observed in the acute dermal toxicity studies conducted with the read across substances lithium bromide and lithium chloride. Additionally, lithium fluoride did not show any skin irritating or skin corrosive properties in two in vitro studies (please refer to IUCLID section 7.3.1). Hence, the penetration is not facilitated due to damage of the skin surface.
Therefore, it can be reliably assumed that lithium fluoride is not able to pass the stratum corneum. Further in vivo testing would be unethical and cannot be scientifically justified with the above argumentation.
Justification for classification or non-classification
The available experimental test data are
reliable and suitable for classification purposes under Regulation (EC)
No 1272/2008. As a result the substance is considered to be classified
as acute toxicity cat. 4, H302: "Harmful if swallowed" under Regulation
(EC) No 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.